MCID: PRS039
MIFTS: 46

Prostate Adenocarcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Adenocarcinoma

Aliases & Descriptions for Prostate Adenocarcinoma:

Name: Prostate Adenocarcinoma 12 13 14
Adenocarcinoma of Prostate 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2526
NCIt 47 C2919
SNOMED-CT 64 399490008
UMLS 69 C0007112

Summaries for Prostate Adenocarcinoma

Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Prostate Adenocarcinoma, also known as adenocarcinoma of prostate, is related to lymphoepithelioma-like acinar prostate adenocarcinoma and prostatitis. An important gene associated with Prostate Adenocarcinoma is WDR19 (WD Repeat Domain 19), and among its related pathways/superpathways are Glioma and DNA Damage Response (only ATM dependent). The drugs Fesoterodine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Related Diseases for Prostate Adenocarcinoma

Diseases related to Prostate Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
id Related Disease Score Top Affiliating Genes
1 lymphoepithelioma-like acinar prostate adenocarcinoma 11.9
2 prostatitis 11.0
3 adenocarcinoma 11.0
4 prostatic acinar adenocarcinoma 10.8
5 prostate signet ring cell adenocarcinoma 10.8
6 prostate colloid adenocarcinoma 10.8
7 vagneur triolle ripert syndrome 10.3 CHGA KLK3
8 vulvar keratoacanthoma-like carcinoma 10.3 CHGA KLK3
9 malt worker's lung 10.2 KLK3 TP53
10 reticulosarcoma 10.2 AR TP53
11 rhinitis 10.2 AMACR KLK3 TP53
12 exocervical carcinoma 10.1 AR ESR2 KLK3
13 colon signet ring adenocarcinoma 10.1 AMACR AR KLK3 TMPRSS2
14 skin hemangioma 10.1 AMACR AR FOLH1 KLK3
15 growth retardation hydrocephaly lung hypoplasia 10.1 CHGA ERBB2 TP53
16 cystinosis, nephropathic 10.1 ERBB2 TP53
17 vulva adenocarcinoma 10.1 AR ERBB2 TP53
18 spinal muscular atrophy with progressive myoclonic epilepsy 10.1 AMACR GSTP1 TP53
19 brown-vialetto-van laere syndrome 10.1 CHGA KLK3 TMPRSS2 TP53
20 lung clear cell-sugar-tumor 10.1 ERBB2 TP53
21 avoidant personality disorder 10.1 AR ESR2 KLK3
22 mediastinum angiosarcoma 10.1 AR ERBB2 TP53
23 breast ductal carcinoma 10.1 PTEN TP53
24 reactive arthritis 10.1 ERBB2 ESR2 TP53
25 congenital bile acid synthesis defect 10.1 AR ERBB2 KLK3 TP53
26 trachea squamous cell carcinoma 10.0 ERBB2 PTEN TP53
27 breast malignant phyllodes tumor 10.0 AR ERBB2 TP53
28 renal pelvis carcinoma 10.0 AMACR KLK3 UPK3A
29 thymus gland disease 10.0 AMACR KLK3 UPK3A
30 fuchs' heterochromic uveitis 10.0 AMACR KLK3 UPK3A
31 necrobiosis lipoidica 10.0 ERBB2 ESR2 KLK3 TP53
32 benign shuddering attacks 10.0 AR CHGA TP53
33 hypogonadotropic hypogonadism 20 with or without anosmia 10.0 ERBB2 GSTP1 PTEN TP53
34 angiolipomatosis, familial 10.0 AR ERBB2 UPK3A
35 pituitary stalk meningioma 9.9 ERBB2 ESR2 PTEN TP53
36 prostatic adenoma 9.9 ERBB2 ESR2 PTEN TP53
37 malignant pleural solitary fibrous tumor 9.9 CHGA ERBB2 KLK3 PTEN TP53
38 ocular melanoma 9.9 ERBB2 GSTP1 PTEN TP53
39 iris spindle cell melanoma 9.9 AMACR CHGA KLK3 UPK3A
40 papillary transitional carcinoma 9.9 KLK3 TP53 UPK3A
41 nevoid hypermelanosis, linear and whorled 9.9 ERBB2 GSTP1 KLK3 PTEN TP53
42 prostate cancer 9.9
43 adenoma 9.9
44 endotheliitis 9.9
45 nephrogenic adenoma 9.9
46 prostate cancer, hereditary, x-linked 1 9.9 AR ESR2 GSTP1 PTEN TP53
47 choroiditis 9.8
48 small cell carcinoma 9.8
49 dysembryoplastic neuroepithelial tumor 9.8 ERBB2 TP53 UPK3A
50 rapsn-related fetal akinesia deformation sequence 9.8 AR BMP6 KLK3 MSMB PTEN

Graphical network of the top 20 diseases related to Prostate Adenocarcinoma:



Diseases related to Prostate Adenocarcinoma

Symptoms & Phenotypes for Prostate Adenocarcinoma

MGI Mouse Phenotypes related to Prostate Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 AIMP1 AMACR AR CHGA ERBB2 ESR2
2 endocrine/exocrine gland MP:0005379 9.92 AR CHGA ERBB2 ESR2 MSMB PTEN
3 limbs/digits/tail MP:0005371 9.63 ERBB2 ESR2 PTEN TP53 WDR19 AR
4 neoplasm MP:0002006 9.5 AR ERBB2 ESR2 MSMB PTEN TMPRSS2
5 reproductive system MP:0005389 9.28 AR BMP6 CHGA ERBB2 ESR2 MSMB

Drugs & Therapeutics for Prostate Adenocarcinoma

Drugs for Prostate Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 444)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Prilocaine Approved Phase 4 721-50-6 4906
4
Somatostatin Approved Phase 4,Phase 2,Phase 3 38916-34-6, 51110-01-1 53481605
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Cholinergic Agents Phase 4
10 Cholinergic Antagonists Phase 4
11 Muscarinic Antagonists Phase 4
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
13 Anesthetics Phase 4,Phase 3,Phase 2
14 Anesthetics, Local Phase 4
15 Anti-Arrhythmia Agents Phase 4
16 Central Nervous System Depressants Phase 4,Phase 3
17 Diuretics, Potassium Sparing Phase 4
18 Sodium Channel Blockers Phase 4
19
Lactitol Phase 4 585-86-4 3871
20
Bicalutamide Approved Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
21
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
22
Goserelin Approved Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
23
Flutamide Approved Phase 3,Phase 2,Phase 1 13311-84-7 3397
24
Leuprolide Approved, Investigational Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Estramustine Approved Phase 3,Phase 1,Phase 2 2998-57-4 18140 259331
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
28
Methyltestosterone Approved Phase 3,Phase 2,Phase 1 58-18-4 6010
29
Testosterone Approved, Investigational Phase 3,Phase 2,Phase 1 58-22-0 6013
30
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
31
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
32
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
33
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
34
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
35
Norepinephrine Approved Phase 3 51-41-2 439260
36
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
37
Ketoconazole Approved, Investigational Phase 3,Phase 2,Phase 1 65277-42-1 47576 3823
38
Nilutamide Approved Phase 3,Phase 2,Phase 1 63612-50-0 4493
39
Vinblastine Approved Phase 3,Phase 1,Phase 2 865-21-4 13342 241903
40
Buserelin Approved Phase 3,Phase 2,Phase 1 57982-77-1
41
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
42
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
43
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
44
Diethylstilbestrol Approved Phase 3 56-53-1 3054 448537
45
Suramin Approved Phase 3,Phase 1 145-63-1 5361
46
Zoledronic acid Approved Phase 3,Phase 2,Phase 1 118072-93-8 68740
47
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
48
Calcium carbonate Approved Phase 3 471-34-1
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
lanreotide Approved Phase 2, Phase 3 108736-35-2

Interventional clinical trials:

(show top 50) (show all 695)
id Name Status NCT ID Phase
1 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Completed NCT01661166 Phase 4
2 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
4 Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy Terminated NCT01365143 Phase 4
5 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3
6 Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer Unknown status NCT00363285 Phase 3
7 Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer Unknown status NCT00104715 Phase 3
8 Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer Unknown status NCT00967863 Phase 3
9 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3
10 Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Unknown status NCT00376792 Phase 3
11 Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer Unknown status NCT00796458 Phase 3
12 Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00003734 Phase 3
13 Androgen Deprivation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00110162 Phase 3
14 Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Unknown status NCT00541047 Phase 3
15 Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma Completed NCT01011751 Phase 3
16 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
17 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed NCT00002855 Phase 3
18 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed NCT00002633 Phase 3
19 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002597 Phase 3
20 Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer Completed NCT00003607 Phase 3
21 Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Completed NCT00065442 Phase 3
22 A Study of Leuprolide to Treat Prostate Cancer Completed NCT00626431 Phase 3
23 Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer Completed NCT00394511 Phase 3
24 Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Completed NCT00182052 Phase 3
25 Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Completed NCT01394263 Phase 3
26 Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer Completed NCT01697384 Phase 3
27 Hormone Therapy in Treating Patients With Advanced Prostate Cancer Completed NCT00003026 Phase 3
28 Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Completed NCT00657904 Phase 3
29 A Long Term Safety Study With Atrasentan Completed NCT00127478 Phase 2, Phase 3
30 Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer Completed NCT00003653 Phase 3
31 Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00027859 Phase 3
32 Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer Completed NCT00067015 Phase 3
33 Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002760 Phase 3
34 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Completed NCT00110214 Phase 3
35 Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer Completed NCT00316927 Phase 3
36 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed NCT00002651 Phase 3
37 S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00004001 Phase 3
38 Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer Completed NCT00002881 Phase 3
39 Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer Completed NCT00023686 Phase 3
40 Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00005947 Phase 3
41 Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer Completed NCT00255606 Phase 3
42 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
43 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3
44 Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002723 Phase 3
45 Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002703 Phase 3
46 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed NCT00079001 Phase 3
47 Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer Completed NCT00003232 Phase 3
48 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy Completed NCT00931528 Phase 3
49 Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy Completed NCT01707966 Phase 3
50 Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer Completed NCT00002511 Phase 3

Search NIH Clinical Center for Prostate Adenocarcinoma

Genetic Tests for Prostate Adenocarcinoma

Anatomical Context for Prostate Adenocarcinoma

MalaCards organs/tissues related to Prostate Adenocarcinoma:

39
Prostate, Bone, Lymph Node, Lung, Endothelial, Skin, Breast

Publications for Prostate Adenocarcinoma

Articles related to Prostate Adenocarcinoma:

(show top 50) (show all 793)
id Title Authors Year
1
Differentiating tumor heterogeneity in formalin-fixed paraffin-embedded (FFPE) prostate adenocarcinoma tissues using principal component analysis of matrix-assisted laser desorption/ionization imaging mass spectral data. ( 27791282 )
2017
2
Risk of lymph node metastases in pathological gleason scorea8o6 prostate adenocarcinoma: Analysis of institutional and population-based databases. ( 27692833 )
2017
3
Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma. ( 27817002 )
2017
4
MULTIMODAL IMAGING AND HISTOLOGIC CORRELATION OF ISOLATED METASTASIS OF PROSTATE ADENOCARCINOMA TO THE CHOROID. ( 27124795 )
2016
5
A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells. ( 26786102 )
2016
6
Neuropathic tremor associated with anti-MAG IgM-monoclonal gammopathy and prostate adenocarcinoma: Which one is the culprit? ( 27036215 )
2016
7
Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma. ( 27527400 )
2016
8
Seminal Vesicle Leiomyoma Mimicking Extra-prostatic Extension ofA Prostatic Adenocarcinoma. ( 27169020 )
2016
9
Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. ( 27452951 )
2016
10
Bilateral Testicular Metastases and Filariasis in Prostatic Adenocarcinoma. ( 28017535 )
2016
11
Metastatic prostate adenocarcinoma presenting as a large right supraclavicular and anterior chest wall mass. ( 27799225 )
2016
12
Survival predictors in patients with prostate adenocarcinoma with hormonal blockade. ( 27502465 )
2016
13
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. ( 27753182 )
2016
14
mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. ( 27096957 )
2016
15
Metastasis of Prostate Adenocarcinoma to the Testis. ( 27703299 )
2016
16
Prostate Adenocarcinoma Metastasis to the Bilateral Ureters: a Rare but Potentially Important Finding. ( 27466304 )
2016
17
Metastasis of prostate adenocarcinoma to the frontal and ethmoid sinus. ( 27909626 )
2016
18
MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: a88A Comparison With AMACR. ( 27543977 )
2016
19
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. ( 27788949 )
2016
20
Gleason Grade 4 Prostate Adenocarcinoma Patterns: An Inter-observer Agreement Study among Genitourinary Pathologists. ( 27028587 )
2016
21
Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma. ( 26341090 )
2016
22
Malakoplakia associated with prostatic adenocarcinoma: Report of 4 cases and literature review. ( 27180057 )
2016
23
Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions. ( 27315446 )
2016
24
(64)Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. ( 27715146 )
2016
25
Prostate adenocarcinoma mandibular metastasis associated with numb chin syndrome: a case report. ( 27847740 )
2016
26
Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. ( 27567208 )
2016
27
Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. ( 27486316 )
2016
28
Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy. ( 27330887 )
2016
29
Generalized Lymphadenopathy of Prostate Adenocarcinoma Origin. A Case Series. ( 26851518 )
2016
30
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. ( 27180064 )
2016
31
9-AAA inhibits growth and induces apoptosis in human melanoma A375 and rat prostate adenocarcinoma AT-2 and Mat-LyLu cell lines but does not affect the growth and viability of normal fibroblasts. ( 27895781 )
2016
32
Bilaterally mammary acanthosis nigricans as paraneoplastic manifestation of prostate adenocarcinoma. ( 27595210 )
2016
33
Role of tumor-associated macrophages in the Hexim1 and TGFI^/SMAD pathway, and their influence on progression of prostatic adenocarcinoma. ( 26608417 )
2016
34
Radiologic presentation of chronic granulomatous prostatitis mimicking locally advanced prostate adenocarcinoma. ( 27257455 )
2016
35
Renal and retroperitoneal metastasis from prostate adenocarcinoma: a case report. ( 26957001 )
2016
36
Incidental Meningioma Mimicking Metastasis of Prostate Adenocarcinoma in 68Ga-Labeled PSMA Ligand PET/CT. ( 27824323 )
2016
37
Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. ( 26818960 )
2016
38
Modification of the pT2 substage classification in prostate adenocarcinoma. ( 27251951 )
2016
39
Reduced expression of the DNA glycosylase gene MUTYH is associated with an increased number of somatic mutations via a reduction in the DNA repair capacity in prostate adenocarcinoma. ( 27253753 )
2016
40
Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and AbraxaneAr for treatment of human prostate adenocarcinoma in mice. ( 27297780 )
2016
41
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma. ( 27051534 )
2016
42
Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming. ( 26773436 )
2016
43
The detection and upgrade rates of prostate adenocarcinoma following transperineal template-guided prostate biopsy - a tertiary referral centre experience. ( 27123325 )
2016
44
Prognostic Significance of Lymphatic Vessel Density Detected by D2-40 and Its Relation to Claudin-4 Expression in Prostatic Adenocarcinoma. ( 26464161 )
2016
45
Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach. ( 26477458 )
2015
46
I9Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. ( 25548110 )
2015
47
Fractal analysis and the diagnostic usefulness of silver staining nucleolar organizer regions in prostate adenocarcinoma. ( 26366372 )
2015
48
Promoter hypermethylation as a biomarker in prostate adenocarcinoma. ( 25421683 )
2015
49
(P070) High-Risk Prostate Adenocarcinoma Treated With Whole-Pelvis Radiotherapy HDR Brachytherapy Boost Results in Very High Disease-Specific Survival. ( 25930841 )
2015
50
A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. ( 25797256 )
2015

Variations for Prostate Adenocarcinoma

ClinVar genetic disease variations for Prostate Adenocarcinoma:

6 (show top 50) (show all 62)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
10 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
21 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
22 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
23 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
25 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
28 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
29 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
30 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
31 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
32 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
33 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
34 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
35 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
36 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
37 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
38 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
39 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
40 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
41 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
42 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
43 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
44 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
45 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
46 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
47 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
48 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
49 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
50 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093

Expression for Prostate Adenocarcinoma

Search GEO for disease gene expression data for Prostate Adenocarcinoma.

Pathways for Prostate Adenocarcinoma

GO Terms for Prostate Adenocarcinoma

Cellular components related to Prostate Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 AIMP1 BMP6 CHGA ESR2 GSTP1 KLK3

Biological processes related to Prostate Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-mediated signaling GO:0048015 9.43 ERBB2 PTEN TP53
2 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.16 AR ERBB2
3 cell proliferation GO:0008283 9.02 AR ERBB2 GRPR PTEN TP53
4 prostate gland growth GO:0060736 8.96 AR PTEN

Sources for Prostate Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....